tbuckley/cabot-search huggingface dataset:
How to Treat Blastic Plasmacytoid Dendritic Cell Neoplasm (BPDCN) Patients : Results on 86 Patients of the French BPDCN Network
Authors: Eve Poret, Chrystelle Vidal, Yohan Desbrosses, Fanny Angelot Delettre, Maider Pagadoy, Aurore Pugin, Louis Benazet, Franck Leroux, Elise Robert, Delphine Binda, Sabeha Biichle, Anne Roggy, Laure Philippe, Berengere Gruson, Anne-Claire Gac, Michel Maigre, Denis Caillot, Remy Gressin, Pascal Turlure, Anne-Sophie Michallet, Lila Gilis, Veronique Dorvaux, Yazid Arkam, Caroline Bonmati, Pierre Péterlin, Pierre-Simon Rohrlich, Thorsten Braun, jean-Valere Malfuson, Didier Bouscary, Eric Pujade-Lauraine, Felipe Suarez, Carole Soussain, Etienne Lengliné, Mathieu Puyade, Tony Marchand, Denis Guyotat, Bruno Lioure, Christian Recher, Damien Roos-Weil, Fabrice Jardin, Jean-Pierre Marolleau, Bernard Drenou, Bernard Bonnotte, Sophie Dalac, Philippe Saas, Francine Garnache Ottou, Eric Deconinck
Journal: Blood (2015)
Safety of everolimus (EVE) in Asian patients (pts) with advanced gastric cancer (AGC) enrolled in the phase III GRANITE-1 study.
Authors: Kun-Huei Yeh, Eric Van Cutsem, Atsushi Ohtsu, Lin Shen, Jaffer A. Ajani, Syed Rizvi, Michaela Sedova, Chiara Costantini, Heind Smith, Tarek Sahmoud, Yung-Jue Bang
Journal: Journal of Clinical Oncology (2012)

4081 Background: Previous subanalyses of the RECORD-1 (Jpn J Clin Oncol 2011;41:17-24) and RADIANT-3 (GICS 2011; abs. 289) studies of the oral mammalian target of rapamycin inhibitor EVE showed that incidences of stomatitis, rash, infections, and pneumonitis were greater in Asian pts; however, the number of Asian pts enrolled was small. GRANITE-1 provides an opportunity to evaluate EVE safety in a broader Asian population. Methods: In the randomized, double-blind, phase 3 GRANITE-1 study, pts aged ≥18 y with confirmed AGC and disease progression after 1 or 2 lines of systemic chemotherapy were randomized 2:1 to EVE 10 mg/d + best supportive care (BSC) or placebo + BSC. Randomization was stratified by region (Asia [China, Japan, Korea, Taiwan, Thailand, Hong Kong] vs rest of world [ROW]) and previous lines of chemotherapy (1 vs 2). Study drug was continued until disease progression or unacceptable toxicity. Adverse events (AEs) were collected throughout the study and for 28 d after final dose of study drug and assessed according to the Common Terminology Criteria for Adverse Events, v 3.0. Primary endpoint was overall survival. Safety was a secondary endpoint. Results: Of the 656 pts in the study, 363 (55%) were enrolled in Asia and received EVE (n=243) or placebo (n=120). EVE did not significantly reduce the risk of death in the overall (HR 0.90; 95% CI 0.75-1.08), Asian (HR 0.96; 95% CI 0.75-1.23), or ROW (HR 0.85; 95% CI 0.65-1.10) populations. The most common any-grade AEs among EVE-treated pts (Asia vs ROW) were decreased appetite (45% vs 51%), stomatitis (44% vs 35%), and fatigue (34% vs 35%). Among EVE-treated pts, rates of any-grade rash, infections, and pneumonitis (Asia vs ROW) were 22% vs 18%, 24% vs 28%, and 4% vs 2%, respectively; rates of grade 3/4 stomatitis, rash, infections, and pneumonitis (Asia vs ROW) were 4% vs 6%, 0% vs 0.5%, 6% vs 9%, and 0.4% vs 1%, respectively. No grade 4 pneumonitis was observed. Only 1 pt (from Asia) discontinued due to pneumonitis (grade 3). Conclusions: The safety profile of EVE in Asian pts with AGC was similar to that observed in ROW pts with AGC and with EVE in other cancers. No new safety signals were identified. Pneumonitis was relatively uncommon in Asian and ROW pts.
Réseau sur la recherche de pathogènes émergents d'origine alimentaire en Allemagne
Authors: D Werber, A Ammon
Journal: Eurosurveillance (2000)

Un reseau d’epidemiologistes, de microbiologistes, de veterinaires et de cliniciens est en cours de developpement en Allemagne. Il vise a encourager les departements de sante locaux et nationaux ainsi que les autorites veterinaires a mener des recherches et des investigations epidemiologiques sur les pathogenes emergents d’origine alimentaire. Cet article decrit les methodes utilisees actuellement pour etudier Escherichia coli enterohemorrhagique (EHEC) et le syndrome hemolytique et uremique (SHU).
Identification of Candidate Oncogenes and Chromosomal Breakpoint Sequencing By Targeted Locus Amplification in T-Cell Acute Lymphoblastic Leukemia
Authors: Eric M Vroegindeweij, Tim Lammens, Erik Splinter, Anne Uyttebroeck, Kirsten Canté-Barrett, Jessica GCAM Buijs-Gladdines, Wilco K Smits, Peter Vandenberghe, Max J van Min, Rob Pieters, Pieter Van Vlierberghe, Jules PP Meijerink
Journal: Blood (2015)
Co-Expression Of The MUC1 Oncoprotein and CD34 On Primary Myeloma Bone Marrow Cells Identifies a Population With Myeloma Initiating Potential
Authors: Katarina Luptakova, Jacalyn Rosenblatt, Dina Stroopinsky, Heidi Mills, Jana Jakubikova, John G Clohessy, Srivastava Neeharika, Baldev Vasir, Hasan Rajabi, Maxwell D Coll, Kristen Palmer, Jon Arnason, Jeffrey Zwicker, Robin Joyce, Ayad Hamdan, James D. Levine, Constantine S. Mitsiades, Kenneth C. Anderson, Donald Kufe, David Avigan
Journal: Blood (2013)
Amelioration of X-Linked Related Autophagy Failure in Danon Disease With DNA Methylation Inhibitor
Authors: Kwong-Man Ng, Pamela Y. Mok, Amy W. Butler, Jenny C.Y. Ho, Shing-Wan Choi, Yee-Ki Lee, Wing-Hon Lai, Ka-Wing Au, Yee-Man Lau, Lai-Yung Wong, Miguel A. Esteban, Chung-Wah Siu, Pak C. Sham, Alan Colman, Hung-Fat Tse
Journal: Circulation (2016)

Danon disease is an X-linked disorder that leads to fatal cardiomyopathy caused by a deficiency in lysosome-associated membrane protein-2 (LAMP2). In female patients, a later onset and less severe clinical phenotype have been attributed to the random inactivation of the X chromosome carrying the mutant diseased allele. We generated a patient-specific induced pluripotent stem cell (iPSCs)-based model of Danon disease to evaluate the therapeutic potential of Xi-chromosome reactivation using a DNA methylation inhibitor.Using whole-exome sequencing, we identified a nonsense mutation (c.520C>T, exon 4) of the LAMP2 gene in a family with Danon disease. We generated iPSC lines from somatic cells derived from the affected mother and her 2 sons, and we then differentiated them into cardiomyocytes (iPSC-CMs) for modeling the histological and functional signatures, including autophagy failure of Danon disease.Our iPSC-CM platform provides evidence that random inactivation of the wild-type and mutant LAMP2 alleles on the X chromosome is responsible for the unusual phenotype in female patients with Danon disease. In vitro, iPSC-CMs from these patients reproduced the histological features and autophagy failure of Danon disease. Administration of the DNA demethylating agent 5-aza-2'-deoxycytidine reactivated the silent LAMP2 allele in iPSCs and iPSC-CMs in female patients with Danon disease and ameliorated their autophagy failure, supporting the application of a patient-specific iPSC platform for disease modeling and drug screening.Our iPSC-CM platform provides novel mechanistic and therapeutic insights into the contribution of random X chromosome inactivation to disease phenotype in X-linked Danon disease.
A recovery program to improve quality of life, sense of coherence and psychological health in ICU survivors: a multicenter randomized controlled trial, the RAPIT study
Authors: Janet F. Jensen, Ingrid Egerod, Morten H. Bestle, Doris F. Christensen, Ask Elklit, Randi L. Hansen, Heidi Knudsen, Louise B. Grode, Dorthe Overgaard
Journal: Intensive Care Medicine (2016)
392. Evaluating Promoter Regulated Dopaminergic Neuron Targeting with AAV9 Delivered To the Neonatal Mouse
Authors: Joanne Ng, Rajvinder Karda, Giulia Massaro, E. Meyer, S. Barrel, J. Baruteau, M. Hughes, D. Perocheau, SMK Buckley, M.A. Kurian, A.A. Rahim, S.N. Waddington
Journal: Molecular Therapy (2015)

Parkinson's disease (PD) is a progressive neurodegenerative disease due to profound degeneration of mid-brain dopaminergic (DA) nigrostriatal neurons. Childhood onset monogenic forms of PD and DA neurotransmitter disorders are increasingly recognised where current medical treatments are ineffective and gene therapy may have significant therapeutic impact. These disorders highlight that gene delivery and expression needs vary and the challenge is to target the DA neurons that require the therapeutic transgene. Adeno-associated virus (AAV) achieves global central nervous system delivery (CNS) following both intracerebroventricular (IC) and intravenous (IV) delivery in neonatal mice. We evaluated the effect of promoter choice on DA neuronal expression following these modes of administration. Using AAV2/9 serotype vectors with different promoters [Tyrosine hydroxylase (rTH), beta glucuronidase B (GUSB), Synapsin (hSyn) with CMV control] expressing green fluorescent protein (GFP) we assessed the brain regions targeted following IC and IV injection to P0 neonatal mice. Transduction profiles were evaluated through direct stereoscopic fluorescence and free floating immunohistochemistry with thresholding intensities at P35. Co-localisation with TH positive neurons was performed with fluorescence immunohistochemistry and confocal microscopy. The most extensive intracranial transduction was achieved with hSyn, followed by GUSB and minimal with rTH promoter. IC delivery demonstrated superior widespread intracranial transduction than IV delivery. TH positive neurons in the substantia nigra were transduced with: rTH promoter (IC =4%, IV=20%), GUSB (IC =6.9%, IV= 0%) hSyn (IC=0%, IV= 24%). Here we observe evidence that targeting mid-brain DA neurons is influenced by both delivery method and promoter following administration to the neonatal mouse brain.
Robust Oncolytic Virotherapy Induces Tumor Lysis Syndrome and Associated Toxicities in the MPC-11 Plasmacytoma Model
Authors: Lianwen Zhang, Michael B Steele, Nathan Jenks, Jacquelyn Grell, Marshall Behrens, Rebecca Nace, Shruthi Naik, Mark J Federspiel, Stephen J Russell, Kah-Whye Peng
Journal: Molecular Therapy (2016)

Tumor-selective oncolytic vesicular stomatitis viruses (VSVs) are being evaluated in clinical trials. Here, we report that the MPC-11 murine plasmacytoma model is so extraordinarily susceptible to oncolytic VSVs that a low dose of virus leads to extensive intratumoral viral replication, sustained viremia, intravascular coagulation, and a rapidly fatal tumor lysis syndrome (TLS). Rapid softening, shrinkage and hemorrhagic necrosis of flank tumors was noted within 1-2 days after virus administration, leading to hyperkalemia, hyperphosphatemia, hypocalcemia, hyperuricemia, increase in plasma cell free DNA, lymphopenia, consumptive coagulopathy, increase in fibrinogen degradation products, decreased liver function tests, dehydration, weight loss, and euthanasia or death after 5-8 days. Secondary viremia was observed but viral replication in normal host tissues was not detected. Toxicity could be mitigated by using VSVs with slowed replication kinetics, and was less marked in animals with smaller flank tumors. The MPC-11 tumor represents an interesting model to further study the complex interplay of robust intratumoral viral replication, tumor lysis, and associated toxicities in cases where tumors are highly responsive to oncolytic virotherapy.
Prognosis after surgical replacement with a bioprosthetic aortic valve in patients with severe symptomatic aortic stenosis: systematic review of observational studies
Authors: Farid Foroutan, Gordon H Guyatt, Kathleen O’Brien, Eva Bain, Madeleine Stein, Sai Bhagra, Daegan Sit, Rakhshan Kamran, Yaping Chang, Tahira Devji, Hassan Mir, Veena Manja, Toni Schofield, Reed A Siemieniuk, Thomas Agoritsas, Rodrigo Bagur, Catherine M Otto, Per O Vandvik
Journal: BMJ (2016)

<b>Objective</b>&nbsp;To determine the frequency of survival, stroke, atrial fibrillation, structural valve deterioration, and length of hospital stay after surgical replacement of an aortic valve (SAVR) with a bioprosthetic valve in patients with severe symptomatic aortic stenosis. <b>Design</b>&nbsp;Systematic review and meta-analysis of observational studies. <b>Data sources</b>&nbsp;Medline, Embase, PubMed (non-Medline records only), Cochrane Database of Systematic Reviews, and Cochrane CENTRAL from 2002 to June 2016. <b>Study selection</b>&nbsp;Eligible observational studies followed patients after SAVR with a bioprosthetic valve for at least two years. <b>Methods</b>&nbsp;Reviewers, independently and in duplicate, evaluated study eligibility, extracted data, and assessed risk of bias for patient important outcomes. We used the GRADE system to quantify absolute effects and quality of evidence. Published survival curves provided data for survival and freedom from structural valve deterioration, and random effect models provided the framework for estimates of pooled incidence rates of stroke, atrial fibrillation, and length of hospital stay. <b>Results</b>&nbsp;In patients undergoing SAVR with a bioprosthetic valve, median survival was 16 years in those aged 65 or less, 12 years in those aged 65 to 75, seven years in those aged 75 to 85, and six years in those aged more than 85. The incidence rate of stroke was 0.25 per 100 patient years (95% confidence interval 0.06 to 0.54) and atrial fibrillation 2.90 per 100 patient years (1.78 to 4.79). Post-SAVR, freedom from structural valve deterioration was 94.0% at 10 years, 81.7% at 15 years, and 52% at 20 years, and mean length of hospital stay was 12 days (95% confidence interval 9 to 15). <b>Conclusion</b>&nbsp;Patients with severe symptomatic aortic stenosis undergoing SAVR with a bioprosthetic valve can expect only slightly lower survival than those without aortic stenosis, and a low incidence of stroke and, up to 10 years, of structural valve deterioration. The rate of deterioration increases rapidly after 10 years, and particularly after 15 years.
The non-medical workforce and its role in surgical training: Consensus recommendations by the Association of Surgeons in Training
Authors: Vimal J. Gokani, Adam Peckham-Cooper, David Bunting, Andrew J. Beamish, Adam Williams, Rhiannon L. Harries
Journal: International Journal of Surgery (2016)

Changes in the delivery of the healthcare structure have led to the expansion of the non-medical workforce (NMW). The non-medical practitioner in surgery (a healthcare professional without a medical degree who undertakes specialist training) is a valuable addition to a surgical firm. However, there are a number of challenges regarding the successful widespread implementation of this role. This paper outlines a number of these concerns, and makes recommendations to aid the realisation of the non-medical practitioner as a normal part of the surgical team. In summary, the Association of Surgeons in Training welcomes the development of the non-medical workforce as part of the surgical team in order to promote enhanced patient care and improved surgical training opportunities. However, establishing a workforce of independent/semi-independent practitioners who compete for the same training opportunities as surgeons in training may threaten the UK surgical training system, and therefore the care of our future patients.
Toward a Deeper Understanding of Nausea, Vomiting, and Pregnancy Loss
Authors: Siripanth Nippita, Laura E. Dodge
Journal: JAMA Internal Medicine (2016)

Our website uses cookies to enhance your experience. By continuing to use our site, or clicking "Continue," you are agreeing to our Cookie Policy | Continue JAMA Internal Medicine HomeNew OnlineCurrent IssueFor Authors Podcast Publications JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry (1919-1959) JN Learning / CMESubscribeJobsInstitutions / LibrariansReprints & Permissions Terms of Use | Privacy Policy | Accessibility Statement 2023 American Medical Association. All Rights Reserved Search All JAMA JAMA Network Open JAMA Cardiology JAMA Dermatology JAMA Forum Archive JAMA Health Forum JAMA Internal Medicine JAMA Neurology JAMA Oncology JAMA Ophthalmology JAMA Otolaryngology–Head & Neck Surgery JAMA Pediatrics JAMA Psychiatry JAMA Surgery Archives of Neurology & Psychiatry Input Search Term Sign In Individual Sign In Sign inCreate an Account Access through your institution Sign In Purchase Options: Buy this article Rent this article Subscribe to the JAMA Internal Medicine journal
Current clinical trials testing the combination of immunotherapy with radiotherapy
Authors: Josephine Kang, Sandra Demaria, Silvia Formenti
Journal: Journal for ImmunoTherapy of Cancer (2016)

Increasing evidence demonstrates that radiation acts as an immune stimulus, recruiting immune mediators that enable anti-tumor responses within and outside the radiation field. There has been a rapid expansion in the number of clinical trials harnessing radiation to enhance antitumor immunity. If positive, results of these trials will lead to a paradigm shift in the use of radiotherapy. In this review, we discuss the rationale for trials combining radiation with various immunotherapies, provide an update of recent clinical trial results and highlight trials currently in progress. We also address issues pertaining to the optimal incorporation of immunotherapy with radiation, including sequencing of treatment, radiation dosing and evaluation of clinical trial endpoints.
PP2A Inhibitor PME-1 Drives Kinase Inhibitor Resistance in Glioma Cells
Authors: Amanpreet Kaur, Oxana V. Denisova, Xi Qiao, Mikael Jumppanen, Emilia Peuhu, Shafiq U. Ahmed, Olayinka Raheem, Hannu Haapasalo, John Eriksson, Anthony J. Chalmers, Pirjo Laakkonen, Jukka Westermarck
Journal: Cancer Research (2016)

Glioblastoma multiforme lacks effective therapy options. Although deregulated kinase pathways are drivers of malignant progression in glioblastoma multiforme, glioma cells exhibit intrinsic resistance toward many kinase inhibitors, and the molecular basis of this resistance remains poorly understood. Here, we show that overexpression of the protein phosphatase 2A (PP2A) inhibitor protein PME-1 drives resistance of glioma cells to various multikinase inhibitors. The PME-1-elicited resistance was dependent on specific PP2A complexes and was mediated by a decrease in cytoplasmic HDAC4 activity. Importantly, both PME-1 and HDAC4 associated with human glioma progression, supporting clinical relevance of the identified mechanism. Synthetic lethality induced by both PME-1 and HDAC4 inhibition was dependent on the coexpression of proapoptotic protein BAD. Thus, PME-1-mediated PP2A inhibition is a novel mechanistic explanation for multikinase inhibitor resistance in glioma cells. Clinically, these results may inform patient stratification strategies for future clinical trials with selected kinase inhibitors in glioblastoma multiforme. Cancer Res; 76(23); 7001-11. ©2016 AACR.
Cytochrome P450 epoxygenase inhibition attenuates hypoxic pulmonary vasoconstriction and pulmonary vascular remodeling
Authors: Peter Pokreisz, I Fleming, L Kiss, E Barbosa-Sicard, B Fisslthaler, Falck, BD Hammock, I Kim, Z Szelid, Pieter Vermeersch, H Gillyns, Marijke Pellens, F Grimminger, Desire Collen, R Busse, Stefan Janssens
Journal: Circulation (2005)
Reanalysis of PACE trial reignites row over chronic fatigue treatment
Authors: Jacqui Wise
Journal: BMJ (2016)

A preliminary reanalysis of the controversial PACE trial into treatment of chronic fatigue syndrome has concluded that the previously reported recovery rates were inflated fourfold and that the recovery rates in the cognitive behavioural therapy (CBT) and graded exercise therapy groups were not significantly higher than in the group of patients who had specialist medical care alone.1

The reanalysis, published on the Virology blog, comes after a five year battle to get the original data released. Alem Matthees, an Australian patient with chronic fatigue syndrome, finally succeeded in getting Queen Mary University of London to release the data under the UK Freedom of Information Act.2 3

However, the team of researchers behind the PACE (pacing, graded activity, and cognitive behaviour therapy: a randomised evaluation) trial have said that their own reanalysis confirmed their original conclusion that CBT and graded exercise therapy, but not adaptive pacing therapy, can moderately improve fatigue and physical function in people with chronic fatigue …
What we need to know when performing and interpreting US elastography
Authors: So Hyun Park, So Yeon Kim, Chong Hyun Suh, Seung Soo Lee, Kyoung Won Kim, So Jung Lee, Moon-Gyu Lee
Journal: Clinical and Molecular Hepatology (2016)

According to the increasing need for accurate staging of hepatic fibrosis, the ultrasound (US) elastography techniques have evolved significantly over the past two decades. Currently, US elastography is increasingly used in clinical practice. Previously published studies have demonstrated the excellent diagnostic performance of US elastography for the detection and staging of liver fibrosis. Although US elastography may seem easy to perform and interpret, there are many technical and clinical factors which can affect the results of US elastography. Therefore, clinicians who are involved with US elastography should be aware of these factors. The purpose of this article is to present a brief overview of US techniques with the relevant technology, the clinical indications, diagnostic performance, and technical and biological factors which should be considered in order to avoid misinterpretation of US elastography results.
Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?
Authors: Pasi M Penttinen, Martin H Friede
Journal: Eurosurveillance (2016)

Preview this article: Decreased effectiveness of the influenza A(H1N1)pdm09 strain in live attenuated influenza vaccines: an observational bias or a technical challenge?, Page 1 of 1 < Previous page | Next page > /docserver/preview/fulltext/eurosurveillance/21/38/eurosurv-21-30350-1-1.gif
Immune Tolerance Induction by High Doses FVIII in Hemophilia A Patients with Inhibitor Does Not Require Deletion of FVIII-Specific T Cells.
Authors: Marc G. Jacquemin, Renaud Lavend’homme, Thérèse Tinot, Kathelijne Peerlinck, Jean Marie Saint-Remy, Brigitte Pautard
Journal: Blood (2006)